MetaVia Inc. Files 8-K on Security Holder Vote Matters

Ticker: MTVA · Form: 8-K · Filed: Jun 30, 2025 · CIK: 1638287

Metavia INC. 8-K Filing Summary
FieldDetail
CompanyMetavia INC. (MTVA)
Form Type8-K
Filed DateJun 30, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, shareholder-vote, filing-update

Related Tickers: MTVA

TL;DR

MetaVia Inc. (MTVA) is having a shareholder vote on June 30, 2025. Big decisions ahead!

AI Summary

On June 30, 2025, MetaVia Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, formerly known as NeuroBo Pharmaceuticals, Inc. and Gemphire Therapeutics Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector.

Why It Matters

This filing indicates a significant corporate event where security holders will be voting on important matters, which could impact the company's future direction and shareholder value.

Risk Assessment

Risk Level: medium — Shareholder votes can lead to significant changes in corporate governance or strategy, introducing uncertainty.

Key Players & Entities

FAQ

What specific matters will be voted on by MetaVia Inc. security holders?

The filing states that it is a 'Submission of Matters to a Vote of Security Holders' but does not specify the exact matters in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on June 30, 2025.

What is MetaVia Inc.'s primary industry?

MetaVia Inc. is classified under Pharmaceutical Preparations [2834].

What were MetaVia Inc.'s previous names?

MetaVia Inc. was formerly known as NeuroBo Pharmaceuticals, Inc. and Gemphire Therapeutics Inc.

Where is MetaVia Inc. headquartered?

MetaVia Inc. is headquartered at 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 30, 2025 regarding MetaVia Inc. (MTVA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing